MétaCan
Menu
Back to cohort
Record W2058534130 · doi:10.1161/strokeaha.113.003379

Stem Cells as an Emerging Paradigm in Stroke 3

2013· review· en· W2058534130 on OpenAlexfundno aff
Sean I. Savitz, Steven C. Cramer, Lawrence R. Wechsler, Jaroslaw Aronowski, Johannes Boltze, Cesar V. Borlongan, Casey Case, Thomas N. Chase, Michael Chopp, S. Thomas Carmichael, Pamela W. Duncan, Seth P. Finklestein, Steven Fischkoff, Raphaël Guzman, David C. Hess, David Huang, Jim Hinson, Steven A. Kautz, Douglas Kondziolka, Robert W. Mays, Vivek Misra, Panos Mitsias, Michel Modo, Keith W. Muir, John D. Sinden, Evan Snyder, Gary K. Steinberg, Farhaan Vahidy, Alison E. Willing, Steven L. Wolf, Ernest W. Yankee, Dileep R. Yavagal

Bibliographic record

VenueStroke · 2013
Typereview
Languageen
FieldMedicine
TopicStroke Rehabilitation and Recovery
Canadian institutionsnot available
FundersDavid Geffen School of Medicine, University of California, Los AngelesNational Institute of Neurological Disorders and StrokeUniversity of California, IrvineUniversity of South CarolinaSchool of Medicine, Emory UniversityFraunhofer-Institut für Zelltherapie und ImmunologieUniversity of GlasgowUniversity of MiamiYork UniversityCelgeneUniversity of PittsburghUniversity of South FloridaEmory University
KeywordsMedicineGerontology

Abstract

fetched live from OpenAlex

C ell-based therapy continues to grow as a new field to explore investigational treatments for stroke. Leaders from academia and industry convened an inaugural meeting in 2007 with members of the National Institutes of Health and Food and Drug Administration (FDA) to generate consensus-based guidelines on the development of cell therapies for stroke, entitled "Stem Cells as an Emerging Paradigm in Stroke" (STEPS). 1 These guidelines focused on preclinical studies that are considered important as part of a development program to support clinical testing of cell therapies. The STEPS meeting also provided recommendations on the conduct of early-stage clinical trials. Given the rapid advances in the field, a second meeting was held in 2009 to update and expand these guidelines, which were published as STEPS 2. Since the prior STEPS meeting, there are now several active cell therapy platforms for stroke and other neurological disorders, in stages that range from preclinical to clinical trials, and with sponsors that include industry, the National Institutes of Health, and the California Institute of Regenerative Medicine. As the field continues to progress and as pilot clinical studies are starting to show safety for some cell types, it has become necessary to formulate a new set of guidelines that address topics not covered in prior STEPS publications. Specifically, the current document reflects a compilation of recommendations that focus on more advanced stages of clinical testing, as well as the testing of cell therapies in a broader stroke population that includes chronic stroke.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Insufficient payload (model declined to judge)
Consensus categoriesInsufficient payload (model declined to judge)
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.990
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.050
GPT teacher head0.353
Teacher spread0.303 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations152
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueStrokeSame topicStroke Rehabilitation and RecoveryFrench-language works237,207